Sequenom AdHoc 27.6. - 500 Beiträge pro Seite

[raimundK]

Datum: 27.06.2000 / Zeit: 12:54:31
Ganz frisch reingekommen (12.00 Uhr, www.finanztreff.de)

SEQUENOM Launches Enhanced High-Throughput Genotyping Technology / 384 SpectroCHIP(TM) Improves Efficiency and Reduces Cost of Analyzing Variations in Human Genome


SAN DIEGO (ots-PRNewswire) - SEQUENOM, Inc. (Nasdaq: SQNM) today
announced the launch of the Company`s proprietary 384
SpectroCHIP(TM). The enhanced technology increases throughput and
reduces costs associated with the large-scale analysis of single
nucleotide polymorphisms (SNPs), genetic variations that are
associated with disease. An essential component of SEQUENOM`s
MassARRAY(TM) system, the SpectroCHIP is now available with a
capacity for both 96 and 384 sample elements. The size of the 384
SpectroCHIP remains the same while significantly increasing sample
density and decreasing volumes, therefore reducing reagent
consumption and cost per sample.

"The new 384 SpectroCHIP offers increased throughput and
substantial cost savings, both of which are essential for industrial
genotyping," said Toni Schuh, Ph.D., SEQUENOM`s President and CEO.
"Designed to hold 10 SpectroCHIPs at a time, our MassARRAY system now
has the capacity of analyzing 3,840 reactions in a single, automated,
unattended run and up to 20,000 reactions per day. This represents a
four-fold increase in sample throughput, which can be even further
increased by multiplexing each reaction. The true power of SEQUENOM
is the combination of advanced technology such as the 384 SpectroCHIP
with application developments that allow us to characterize genetic
variations. The accuracy of the MassARRAY technology also allows for
automated assay development and the analysis of SNPs in a single
sample pool containing DNA from hundreds of individuals. We believe
that these advancements position SEQUENOM to lead the race in mining
the medical utility of SNPs."

According to Charles R. Cantor, Ph.D., SEQUENOM`s Chief Scientific
Officer and co-founder of the Human Genome Project, determining which
SNPs in the human genome are associated with health and disease will
play a critical role in improving drug development and diagnostics,
which will eventually lead to personalized medicine.

"The completion of the human genome sequence presents us with a
template from which to identify variations in individual sequences
and better understand the genetic basis of human disease," said Dr.
Cantor. "The challenge now lies in validating the estimated 10
million SNPs contained within the genome, only a fraction of which
are believed to be medically relevant. The extremely accurate and
robust MassARRAY system provides an unparalleled resource to expedite
this effort, and the improved efficiency of the 384 SpectroCHIP is an
important step."

SpectroCHIPs serve as high-density launching pads for the analysis
of a variety of biomolecules, such as DNA, for use with the MassARRAY
system. This is essential for the automation of mass spectrometry.
The high precision surface structure of the SpectroCHIP allows very
small samples to be accurately positioned and distributed for
analysis. The MassARRAY system then separates, detects and
characterizes the SNPs according to their different molecular
weights.

SEQUENOM is a pioneer in the new field of Industrial Genomics(TM),
the large-scale commercial use of the understanding of DNA variations
for improving health and agriculture. The Company`s MassARRAY system
represents a novel approach to genotyping by combining its
proprietary enzymology, bioinformatics and a miniaturized chip-based
format with the proven technology of mass spectrometry. The result is
a highly accurate, cost-effective technology that addresses the
demand for high throughput SNP analysis and supports strategies to
implement genomic studies based on true full genome scans. SEQUENOM
is headquartered in San Diego, Calif. with offices in Hamburg,
Germany and Boston, Mass.

This press release contains forward-looking statements that
involve risks and uncertainties. These risks and uncertainties
include uncertain or fluctuating customer requirements, fluctuations
in product performance, dependence on the efforts of third parties, a
new and uncertain technology employed by SEQUENOM and its uncertain
application to the needs of individual customers and the competitive
nature of SEQUENOM`s industry, as well as other risks and
uncertainties detailed from time to time in SEQUENOM`s filings with
the Securities and Exchange Commission, including SEQUENOM`s annual
report on Form 10-K for the year ended December 31, 1999 and its most
recent quarterly report on Form 10-Q. Actual results may differ
materially from those projected herein. The forward-looking
statements contained herein represent the judgment of SEQUENOM as of
the date of this release. SEQUENOM disclaims any intent or obligation
to update any of these forward-looking statements.

ots Original Text Service: SEQUENOM, Inc.
Internet: http://recherche.newsaktuell.de

Contact: Abigail Devine, APR, Investor Relations of SEQUENOM, Inc.,
858-350-0345, [e-mail]; or Media: Ana Kapor of
Noonan/Russo Communications, 415-677-4455, ext. 207,
[e-mail]

Web site: http://www.sequenom.com


Klingt doch gut, oder? Weiß einer, warum die nicht mit den anderen SNP-Werten gestern abend raufgegangen sind? Wenn eine Firma von der Genentschlüsselung profitiert, dann Sequenom. Ich schätze, wir werden an der Nasdaq einen Rebound erleben. Ich lege jedenfalls erstmal ein paar Stücke nach.

Ciao, R.

[Tasillo]

Hallöchen zusammen!!

Könnet SQNM eine zweite Quiagen werden???
Als "Zuarbeiter" der Genindustrie mit diesen phantastischen Umsatzsteigerungen Laut BIOTECH-INVESTOR:
"Ausgehend von Umsätzen von 9 Mio USD 2000 soll hier bis 2003 eine glatte Verzehnfachung auf 90 MIO USD erreichbar sein ...".
hätte sie die Chance dazu ??????

[tweety99]

Hallo zusammen,
ja, ich halte Sequqnom mit für das interessanteste und unterbewerteste Unternehmen der Biotechbranche. SQNM wird als erstes von der Genom-Forschung profitieren. Die News von heute sprechen ja schon Bände. Wer klug ist, beobachtet den Markt und steigt bei günstigen Kursen ein.
Gruß
Tweety99

[Tasillo]

.. . oder anders gefragt:
Könnte eine andere Biotech -Firma mit einem Konkurenzprodukt SQNM die Butter vom Brot nehmen und der Kurs von
SQNM
für immer auf Tauchstation gehen????
Wie anfällig ist dehren Produkt für ein solches Szenario ???

Grüsse Tasillo